AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25872787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg daily
Number of subjects: 31
Study 25872904 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) analysis
Number of subjects: 450
Study 25872904 — intervention group
Group type: COMPARATOR
Intervention: Exercise Stress Testing (EST)
Number of subjects: 450
Study 25873979 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic Breathing (YB) - two exercises for ten minutes each, total of twenty minutes in a single session.
Number of subjects: 20
Study 25873979 — intervention group
Group type: COMPARATOR
Intervention: Attention Controls (AC) - reading a text of choice for 20 minutes.
Number of subjects: 20
Study 25874001 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0530 50 mg
Number of subjects: 24
Study 25874001 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0530 100 mg
Number of subjects: 24
Study 25874001 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0530 125 mg
Number of subjects: 24
Study 25874001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25874991 — intervention group
Group type: EXPERIMENTAL
Intervention: TwHF extract (10 mg three times daily for 12 months)
Number of subjects: 18
Study 25876471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 1272
Study 25876471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25mg
Number of subjects: 1272
Study 25876471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study 25876473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 1292
Study 25876473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25mg
Number of subjects: 1292
Study 25876473 — intervention group
Group type: COMPARATOR
Intervention: Interferon β-1a intramuscular 30μg
Number of subjects: 1292
Study 25876560 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study 25876560 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 25877437 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk factors assessment (obesity, depressive symptoms, smoking)
Number of subjects: 630
Study 25877635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α) 6 MIU
Number of subjects: 10
Study 25877635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α)
Number of subjects: 10
Study 25877635 — intervention group
Group type: COMPARATOR
Intervention: Interferon-beta (IFN-β)
Number of subjects: 10
Study 25877962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine for 3 days + primaquine
Number of subjects: 107
Study 25877962 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine for 3 days + no primaquine
Number of subjects: 107
Study 25877962 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple mutant (Cys580Tyr)
Number of subjects: 107
Study 25877962 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-triple mutant
Number of subjects: 107
Study 25878323 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular-nodal stimulation (AVNS)
Number of subjects: 44
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity group (CTRP3 levels)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects (CTRP3 levels)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with waist circumference (WC)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with waist-to-hip ratio (WHR)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with homeostasis model assessment of IR (HOMA-IR)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with triglycerides (TG)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with fasting blood glucose (FBG)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with fasting insulin (FINS)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with homeostasis model assessment of β-cell insulin secretion (HOMA-β)
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple stepwise regression analysis
Number of subjects: 246
Study 25878729 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRP3 as an independent factor
Number of subjects: 246
Study 25879416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (≤8 mg/24 h) as add-on to oral DA
Number of subjects: 90
Study 25879713 — intervention group
Group type: EXPERIMENTAL
Intervention: Early response (≤72 hours) with Definition 1 (resolution of fever within 72 hours)
Number of subjects: 600
Study 25879713 — intervention group
Group type: EXPERIMENTAL
Intervention: Early response (≤72 hours) with Definition 2
Number of subjects: 600
Study 25879713 — intervention group
Group type: COMPARATOR
Intervention: No early response (Definition 1)
Number of subjects: 600
Study 25879713 — intervention group
Group type: COMPARATOR
Intervention: No early response (Definition 2)
Number of subjects: 600
Study 25879747 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET/CT using the Deauville five-point scale (5-PS)
Number of subjects: 63
Study 25879747 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET/CT using ΔSUVmax
Number of subjects: 63
Study 25879747 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET/CT using ΔMTV2.5
Number of subjects: 63
Study 25879747 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined approach using visual, SUV-based, and MTV-based assessment
Number of subjects: 63
Study 25879747 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable group based on combined assessment
Number of subjects: 63
Study 25879807 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0
Study 25879807 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (particularly antialdosteronic diuretic agents)
Number of subjects: 0
Study 25879867 — intervention group
Group type: COMPARATOR
Intervention: One dose of MVA
Number of subjects: 745
Study 25879867 — intervention group
Group type: COMPARATOR
Intervention: Two doses of MVA
Number of subjects: 745
Study 25879867 — intervention group
Group type: COMPARATOR
Intervention: Two doses of placebo
Number of subjects: 745
Study 25879867 — intervention group
Group type: COMPARATOR
Intervention: Single dose of MVA (for vaccinia-experienced subjects)
Number of subjects: 745
Study 25879867 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vaccination with MVA
Number of subjects: 745
Study 25880400 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily for 12 weeks (with optional increase to 120 mg after 8 weeks)
Number of subjects: 32
Study 25880400 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily for 12 weeks
Number of subjects: 32
Study 25880823 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal HIV Test and Treat (UTT) strategy
Number of subjects: 0
Study 25880823 — intervention group
Group type: EXPERIMENTAL
Intervention: TasP intervention package
Number of subjects: 0
Study 25880823 — intervention group
Group type: EXPERIMENTAL
Intervention: UTT implementation
Number of subjects: 0
Study 25881074 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour waist-worn accelerometer protocol in U.S. ISCOLE children
Number of subjects: 1077
Study 25881074 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking wear time for U.S. ISCOLE children
Number of subjects: 1077
Study 25881074 — intervention group
Group type: COMPARATOR
Intervention: Waking wear time for NHANES children
Number of subjects: 1077
Study 25881074 — intervention group
Group type: COMPARATOR
Intervention: Comparison of waking wear time
Number of subjects: 1077
Study 25881074 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour waist-worn accelerometry protocol
Number of subjects: 1077
Study 25881074 — intervention group
Group type: COMPARATOR
Intervention: 24-hour protocol vs waking wear time protocol
Number of subjects: 1077
Study 25881192 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet recruitment strategy
Number of subjects: 45
Study 25881192 — intervention group
Group type: COMPARATOR
Intervention: Diabetes clinics
Number of subjects: 45
Study 25881192 — intervention group
Group type: COMPARATOR
Intervention: Disease register
Number of subjects: 45
Study 25881582 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxometric analysis using MAXCOV/MAMBAC
Number of subjects: 3721
Study 25881582 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-theoretic latent distribution modeling (ITLDM)
Number of subjects: 3721
Study 25881582 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural equation mixture modeling (SEMM)
Number of subjects: 3721
Study 25881847 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan and fludarabine (Flu-BU) conditioning regimen after FLAG-IDA chemotherapy
Number of subjects: 16
Study 25881847 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan and fludarabine (Flu-BU) conditioning regimen
Number of subjects: 16
Study 25881930 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker (LCP)
Number of subjects: 31
Study 25882172 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa-IPV booster dose
Number of subjects: 211
Study 25882172 — intervention group
Group type: COMPARATOR
Intervention: dTpa-IPV
Number of subjects: 211
Study 25882172 — intervention group
Group type: COMPARATOR
Intervention: dTpa+IPV
Number of subjects: 211
Study 25882172 — intervention group
Group type: COMPARATOR
Intervention: Td-IPV
Number of subjects: 211
Study 25882205 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 25882205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 25882205 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25882434 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal angina index (RAI) and biomarkers (NGAL, KIM-1, l-FABP, IL-18)
Number of subjects: 5000
Study 25882434 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal angina index (RAI)
Number of subjects: 5000
Study 25882434 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of biomarkers with RAI
Number of subjects: 5000
Study 25882487 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atherosclerosis presence
Number of subjects: 4184
Study 25882487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate and generalized atherosclerosis
Number of subjects: 4184
Study 25882487 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque presence
Number of subjects: 4184
Study 25882487 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcification
Number of subjects: 4184
Study 25882487 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical disease in low FHS risk
Number of subjects: 4184
Study 25882487 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical disease in high FHS risk
Number of subjects: 4184
Study 25882607 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA levels from 0 to 3.0 cmH₂O/μV, applied in steps of 0.3 cm H₂O/μV every 3 minutes
Number of subjects: 12
Study 25882607 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching EAdipk between non-assisted and assisted breaths
Number of subjects: 12
Study 25883641 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine protein supplement (MPS)
Number of subjects: 60
Study 25883641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25883789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salt and water
Number of subjects: 50
Study 25883789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous isotonic saline
Number of subjects: 50
Study 25884189 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 DNA vaccine (4 mg intramuscularly with Biojector, 3 doses at 4-week intervals)
Number of subjects: 38
Study 25884189 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV boost (licensed H1N1 MIV)
Number of subjects: 38
Study 25884189 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 DNA vaccine
Number of subjects: 38
Study 25884189 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV boost
Number of subjects: 38
Study 25884256 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 218
Study 25884256 — intervention group
Group type: COMPARATOR
Intervention: Microsurgery
Number of subjects: 218
Study 25884259 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs) with perianeurysmal edema (PAE)
Number of subjects: 69
Study 25884259 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs) of the middle cerebral artery (MCA)
Number of subjects: 69
Study 25884259 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs) of the cavernous internal carotid artery (ICA)
Number of subjects: 69
Study 25884259 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs) with PAE
Number of subjects: 69
Study 25884259 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs)
Number of subjects: 69
Study 25884460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU/day)
Number of subjects: 7020
Study 25884460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (4000 IU/day)
Number of subjects: 7020
Study 25884460 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7020
Study 25884460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 7020
Study 25884460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 7020
Study 25884515 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg administrated p.o. twice daily for 28-day treatment cycles
Number of subjects: 11
Study 25884515 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg administrated p.o. twice daily
Number of subjects: 11
Study 25884546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients' knowledge about family history (FH) of cardiovascular disease (CVD)
Number of subjects: 257
Study 25884546 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about FH of stroke
Number of subjects: 257
Study 25884546 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about FH of stroke in grandmothers
Number of subjects: 257
Study 25884546 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of FH reporting by sex
Number of subjects: 257
Study 25884546 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about CAD compared to stroke
Number of subjects: 257
Study 25884954 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-Apgar
Number of subjects: 1855
Study 25884954 — intervention group
Group type: COMPARATOR
Intervention: Specified-Apgar
Number of subjects: 1855
Study 25884954 — intervention group
Group type: COMPARATOR
Intervention: Expanded-Apgar
Number of subjects: 1855
Study 25885260 — intervention group
Group type: COMPARATOR
Intervention: KCC (King's College Criteria)
Number of subjects: 803
Study 25885260 — intervention group
Group type: COMPARATOR
Intervention: KCC-CART (KCC Classification and Regression Tree)
Number of subjects: 803
Study 25885260 — intervention group
Group type: COMPARATOR
Intervention: NEW-CART (using MELD, lactate, mechanical ventilation)
Number of subjects: 803
Study 25885289 — intervention group
Group type: EXPERIMENTAL
Intervention: TG/HDL-C ratio >3.29
Number of subjects: 197
Study 25885289 — intervention group
Group type: EXPERIMENTAL
Intervention: TG/HDL-C ratio
Number of subjects: 197
Study 25885289 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ADMA levels
Number of subjects: 197
Study 25885289 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus
Number of subjects: 197
Study 25885436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine cardiovascular magnetic resonance (DCMR) stress testing
Number of subjects: 278
Study 25885482 — intervention group
Group type: EXPERIMENTAL
Intervention: PIN3 survey
Number of subjects: 42
Study 25885553 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Imiquimod (IMQ) cream, applied once a day, 5 days per week, for 8-16 weeks
Number of subjects: 24
Study 25885553 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Imiquimod (IMQ) cream for lesions >10 mm
Number of subjects: 24
Study 25885553 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Imiquimod (IMQ) cream for lesions <10 mm
Number of subjects: 24
Study 25885665 — intervention group
Group type: EXPERIMENTAL
Intervention: Total leukocyte count
Number of subjects: 500
Study 25885665 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 500
Study 25885665 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte count
Number of subjects: 500
Study 25885799 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate altitude (1,900 m) hiking vacation
Number of subjects: 14
Study 25885799 — intervention group
Group type: COMPARATOR
Intervention: Low altitude (300 m) hiking vacation
Number of subjects: 14
Study 25886014 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine training and counselling via video conference
Number of subjects: 50
Study 25886021 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) dispersible formulation, 20 mg artemether/120 mg lumefantrine, given twice-daily for three days
Number of subjects: 20
Study 25886021 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic data for artemether and dihydroartemisinin
Number of subjects: 20
Study 25886021 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day regimen of AL dispersible formulation
Number of subjects: 20
Study 25886021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing recommendations for infants <5 kg
Number of subjects: 20
Study 25886058 — intervention group
Group type: EXPERIMENTAL
Intervention: IRE ablation
Number of subjects: 10
Study 25886058 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 10
Study 25886058 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS imaging
Number of subjects: 10
Study 25886275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) with capecitabine and radiotherapy
Number of subjects: 41
Study 25886363 — intervention group
Group type: EXPERIMENTAL
Intervention: PROP observational prospective cohort study
Number of subjects: 750
Study 25886388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate Terrorism (IT)
Number of subjects: 613
Study 25886388 — intervention group
Group type: COMPARATOR
Intervention: Situational Couple Violence (SCV)
Number of subjects: 613
Study 25886410 — intervention group
Group type: EXPERIMENTAL
Intervention: CLART HPV2 genotyping assay
Number of subjects: 401
Study 25886410 — intervention group
Group type: COMPARATOR
Intervention: Linear Array (LA)
Number of subjects: 401
Study 25886410 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture 2 (HC2)
Number of subjects: 401
Study 25886603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.03 ml)
Number of subjects: 4
Study 25886605 — intervention group
Group type: EXPERIMENTAL
Intervention: Panagen (5 mg, 6 tablets daily for 18 days during chemotherapy)
Number of subjects: 80
Study 25886605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 tablets daily for 18 days during chemotherapy)
Number of subjects: 80
Study 25886678 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 16 weeks
Number of subjects: 0
Study 25886727 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroRNAs as potential biomarkers and therapeutic targets after cardiac arrest
Number of subjects: 0
Study 25886727 — intervention group
Group type: COMPARATOR
Intervention: Current predictive methods and biomarkers
Number of subjects: 0
Study 25886752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Smokers via web-based video instruction with phone support
Number of subjects: 26
Study 25886793 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV-NAVA (60 minutes)
Number of subjects: 13
Study 25886845 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult Colonoscopy Score (DCS) > 1
Number of subjects: 616
Study 25886845 — intervention group
Group type: COMPARATOR
Intervention: Difficult Colonoscopy Score (DCS) ≤ 1
Number of subjects: 616
Study 25886845 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult Colonoscopy Score (DCS)
Number of subjects: 616
Study 25886928 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine + didanosine
Number of subjects: 1594
Study 25886928 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine (cumulative exposure ≥ 1 year)
Number of subjects: 1594
Study 25886928 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir (cumulative exposure ≥ 1 year)
Number of subjects: 1594
Study 25886928 — intervention group
Group type: EXPERIMENTAL
Intervention: emtricitabine (cumulative exposure ≥ 1 year)
Number of subjects: 1594
Study 25887027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure titration from 65 mmHg to normal levels
Number of subjects: 19
Study 25887045 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-adaptive randomization
Number of subjects: 0
Study 25887094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanroom sleeping environment for two weeks
Number of subjects: 10
Study 25887097 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 58
Study 25887097 — intervention group
Group type: COMPARATOR
Intervention: Patients with smoking status
Number of subjects: 58
Study 25887097 — intervention group
Group type: COMPARATOR
Intervention: Patients with smoking cessation
Number of subjects: 58
Study 25887097 — intervention group
Group type: COMPARATOR
Intervention: Patients with cystic lesions
Number of subjects: 58
Study 25887336 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 150 mg dose of fluconazole
Number of subjects: 157
Study 25887461 — intervention group
Group type: EXPERIMENTAL
Intervention: ReDO™ program
Number of subjects: 84
Study 25887461 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' rating
Number of subjects: 84